Handbook of clinical drug data - part 10 doc
... 916 dialysis, 969 hepatotoxicity, 830 interaction with lab test, 107 0 107 2, 107 4 107 6, 107 8 107 9 interaction with P450 enzyme, 102 1 102 2 in migraine, 6 nephrotoxicity, 841, 843 pregnancy, 880 skin ... Dehydrogenase (S) units/L units/L Child 60–170 60–170 Adult 100 –190 100 –190 >60 yr 110 210 110 210 Isozymes (S) % of Total Fraction of Total Fraction 1 14–26 0.14–0.26 F...
Ngày tải lên: 09/08/2014, 15:20
... nearly all isolates of Staphylococcus aureus and some isolates of coagulase-negative staphylococci are susceptible to these drugs. Methicillin- (actually -lactam-) resistant staphylo- cocci have altered ... maximum of 8 g/day, de- pending on severity and site of infection. Reduce maintenance dosage by 50% with a Cl cr of 10 30 mL/min and by 75% with a Cl cr < ;10 mL/min. Give o...
Ngày tải lên: 09/08/2014, 15:20
... Alfa-2a and 2b are 100 % bioavailable after IM or SC administration, with an absorption half-life of about 6 hr. IM or SC INTERFERON ALFA: ALFA-2A Pegasys, Roferon-A ALFA-2B Intron A, PEG-Intron ALFA-N3 ... interrupted at a number of enzymatic sites, including the conver- sion of inosinic acid to adenine- or xanthine-based ribosides. DNA and RNA syn- thesis is halted in a cell-cycle S-...
Ngày tải lên: 09/08/2014, 15:20
Handbook of clinical drug data - part 4 pptx
... WHICH TO CONSIDER DRUG THERAPY CHD or CHD risk equivalents (1 0- yr risk >20%) < ;100 mg/dL 100 mg/dL ≥130 mg/dL (100 –129 mg/dL: drug therapy optional) 2+ risk factors (1 0- yr risk ≤20%) <130 ... bioavailable be- cause of extensive first-pass elimination; bioavailability increases in liver disease. 251 Covera-HS provides a 4- to 5-hr delay before releasing the drug. Ver- a...
Ngày tải lên: 09/08/2014, 15:20
Handbook of clinical drug data - part 5 ppt
... the first of a class of selective serotonin-5-HT 1A re- ceptor partial agonists. It also has some effect on dopamine-D 2 autoreceptors and, like antidepressants, can downregulate -adrenergic ... hepatically metabolized via CYP3A4 to the 1-hydroxy- and 4-hydroxy-metabolites; the 1-hydroxy-metabolite is at least as active as midazo- lam. Midazolam’s half-life is 1.8–6.4 hr. Adverse Reacti...
Ngày tải lên: 09/08/2014, 15:20
Handbook of clinical drug data - part 6 pdf
... Selectivity of 5-HT 3 receptor antagonists and anti-emetic mechanisms of action. Anticancer Drugs 1992;3:79–85. 88. Holdsworth MT et al. Assessment of chemotherapy-induced emesis and evaluation of a ... 1984;2:930–6. 100 . Covington TR et al., eds. Handbook of nonprescription drugs. 11th ed. Washington, DC: American Pharma- ceutical Association; 1996. 101 . Schiller LR. Clinica...
Ngày tải lên: 09/08/2014, 15:20
Handbook of clinical drug data - part 7 ppt
... of a dose is present in serum as the parent drug and conjugated medroxyprogesterone; it is hydroxylated to 6- -hydroxy-MPA and 21-hydroxy-MPA, which have unknown activities. From 15% to 20% of ... metabolism. Long-term use of griseofulvin can increase men- strual irregularities. 76,96 ,103 ,104 ,108 Parameters to Monitor. Complete pretreatment physical examination with spe- cial re...
Ngày tải lên: 09/08/2014, 15:20
Handbook of clinical drug data - part 8 pptx
... ed. Handbook of non- prescription drugs. 10th ed. Washington, DC: American Pharmaceutical Association; 1993:89–115. 75. American Academy of Pediatrics. Committee on Drugs. Use of codeine- and ... activity of the product. From references 20 and 68–70. 807 ch10.qxd 8/13/2001 2:46 PM Page 807 Drug- Induced Hepatotoxicity This table includes only those drugs with well-established recor...
Ngày tải lên: 09/08/2014, 15:20
Handbook of clinical drug data - part 9 pps
... EVALUATING DRUG DATA FOR THE ELDERLY Because of age-related changes that may impact the outcome of drug therapy as outlined in this chapter, the results of drug studies using young subjects cannot al- ways ... SESSION) (continued ) DRUG REFERENCES DRUG REFERENCES Piperacillin 103 105 Sulfamethoxazole 114 Primidone 106 , 107 Ticarcillin 115 Procainamide 108 , 109 Tocaini...
Ngày tải lên: 09/08/2014, 15:20